Global Alliance for TB Drug Development
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.tballiance.org
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
Phase 2
Active, not recruiting
- Conditions
- Pulmonary TBPulmonary TuberculosisDrug Sensitive Tuberculosis
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 300
- Registration Number
- NCT06058299
- Locations
- 🇵ðŸ‡
Care Clinical Trial Group Inc., Dasmariñas, Philippines
🇬🇪National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
🇵ðŸ‡Tropical Disease Foundation, Makati City, Philippines
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
Phase 1
Completed
- Conditions
- Multi Drug Resistant TuberculosisDrug Sensitive TuberculosisPulmonary DiseaseDrug-resistant TuberculosisMycobacterium Tuberculosis InfectionTuberculosis, PulmonaryTuberculosis
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 28
- Registration Number
- NCT05526911
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 106
- Registration Number
- NCT04890535
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects
Phase 1
Completed
- Conditions
- TuberculosisTuberculosis, Pulmonary
- Interventions
- Drug: 1800 mg TBI-223Drug: TBI-223 PlaceboDrug: 2400mg TBI-223Drug: 3000mg TBI-223
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 28
- Registration Number
- NCT04865536
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
Phase 1
Completed
- Conditions
- Pulmonary DiseaseDrug-resistant TuberculosisTuberculosis, PulmonaryTuberculosisMulti Drug Resistant TuberculosisDrug Sensitive TuberculosisMycobacterium Tuberculosis Infection
- Interventions
- Drug: TBAJ-876 10mgDrug: Matching Placebo for TBAJ-876 tabletDrug: TBAJ-876 25mgDrug: TBAJ-876 50mgDrug: TBAJ-876 100mgDrug: TBAJ-876 200mgDrug: TBAJ-876 400mgDrug: TBAJ-876 Dose XXXmg for Food cohortDrug: TBAJ-876 XXXmg for Part 2
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 107
- Registration Number
- NCT04493671
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 48
- Registration Number
- NCT04309656
- Locations
- 🇺🇸
Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis
Phase 2
Completed
- Conditions
- Tuberculosis, PulmonaryTuberculosis, Multidrug-ResistantTuberculosisTuberculosis, MDRDrug-Resistant Tuberculosis
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 26
- Registration Number
- NCT04179500
- Locations
- 🇿🇦
CHRU, Sizwe Tropical Diseases Hospital, Johannesburg, South Africa
🇿🇦Isango Lethemba TB Research Unit Empilweni TB Hospital, Port Elizabeth, South Africa
🇿🇦The Aurum Institute: Rustenburg Clinical Research Centre, Rustenburg, South Africa
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults
Phase 1
Completed
- Conditions
- TuberculosisTuberculosis, Pulmonary
- Interventions
- Drug: TBI-223 oral suspensionDrug: Placebo suspensionDrug: TBI-223 SR Tablet Prototype 1Drug: TBI-223 SR Tablet Prototype 2Drug: TBI-223 SR Tablet Prototype 3Drug: TBI-223 IR TabletDrug: TBI-223 enteric capsule
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 86
- Registration Number
- NCT03758612
- Locations
- 🇺🇸
Worldwide Clinical Trials (WCT), San Antonio, Texas, United States
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
Phase 2
Completed
- Conditions
- Tuberculosis, PulmonaryTuberculosis, Multidrug-ResistantTuberculosis, MDRTuberculosisDrug-Resistant Tuberculosis
- Interventions
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 455
- Registration Number
- NCT03338621
- Locations
- 🇿🇦
University of Cape Town Lung Institute, Cape Town, South Africa
🇿🇦Madibeng Centre for Research, Brits, South Africa
🇿🇦CHRU, Empilweni TB Hospital, Port Elizabeth, South Africa
A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 6
- Registration Number
- NCT03202693
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath